Didier Pruneau

Biography

Didier Pruneau, Ph.D., is our Chief Scientific Officer. From 1983 to 2005, Dr. Pruneau was Head of the Department of Pharmacology at Fournier Pharma, then, from 2006 to 2009, he was Head of Scientific Operations at Fovea, and then from 2009 to 2013, Head of the Scientific Evaluation and Drug Discovery Ophthalmology Division at Sanofi. Dr. Pruneau has expertise in pharmacology of G-protein coupled receptors, nuclear receptors and ion channels. Dr. Pruneau set up and led drug discovery programs in cardiovascular diseases, traumatic brain injury, skin diseases (wound healing), pain, metabolic diseases and ocular diseases, such as ARMD, diabetic retinopathy, glaucoma, ocular surface inflammatory diseases. Dr. Pruneau received a Ph.D. in biochemistry from Dijon University and a master’s degree in pharmacology from Paris V University, followed by a fellowship in cardiovascular pharmacology in Melbourne, Australia. 

Research Interest

Bioinformatics & Systems Biology